drugset
Drugs / Sacituzumab Govitecan
last change 10 days ago re-read 8 days ago

Sacituzumab Govitecan

also known as Sacituzumab govitecan-hziy · IMMU-132 · Trodelvy · hRS7-SN38 · HRS7-SN38-ANTIBODY-DRUG-CONJUGATE · SG

Monoclonal antibody targets TACSTD2, TOP1 via inhibition

Developed for
triple-negative breast carcinoma · breast cancer · non-small cell lung carcinoma · urothelial carcinoma · female breast carcinoma · hormone receptor-positive breast cancer · cancer · infiltrating bladder urothelial carcinoma
+64 more · small cell lung carcinoma · invasive breast carcinoma · metastatic malignant neoplasm in the brain · endometrial cancer · glioblastoma · malignant epithelial tumor of ovary · urinary bladder cancer · cervical cancer · colorectal cancer · endometrial carcinoma · head and neck squamous cell carcinoma · Her2-receptor negative breast cancer · metastatic malignant neoplasm · metastatic neoplasm · ovarian carcinoma · primary peritoneal carcinoma · salivary gland cancer · bladder adenocarcinoma · bladder small cell carcinoma · bladder squamous cell carcinoma · castration-resistant prostate carcinoma · cervical carcinoma · differentiated thyroid carcinoma · digestive system cancer · disease of genetic or genomic mechanism · esophageal cancer · esophageal squamous cell carcinoma · fallopian tube carcinoma · fallopian tube endometrioid adenocarcinoma · fallopian tube serous adenocarcinoma · gastric adenocarcinoma · gastroesophageal adenocarcinoma · hepatocellular carcinoma · HER2 positive breast carcinoma · hilar cholangiocarcinoma · hormone-resistant prostate carcinoma · hypopharynx squamous cell carcinoma · kidney medullary carcinoma · laryngeal squamous cell carcinoma · lung cancer · malignant leptomeningeal tumor · malignant pancreatic neoplasm · nasal cavity cancer · neuroendocrine neoplasm · oral cavity squamous cell carcinoma · oropharynx squamous cell carcinoma · ovarian cancer · ovarian endometrioid adenocarcinoma · pancreatic adenocarcinoma · paranasal sinus cancer · pleural mesothelioma · primary peritoneal serous/papillary carcinoma · prostate cancer · renal cell carcinoma · renal pelvis/ureter urothelial carcinoma · salivary gland carcinoma · small cell carcinoma · squamous cell carcinoma of penis · thymic carcinoma · thymoma · thyroid cancer · thyroid gland undifferentiated (anaplastic) carcinoma · urinary bladder neoplasm · urinary bladder carcinoma
Investigated by
Gilead Sciences · National Cancer Institute (NCI) · Merck Sharp & Dohme LLC · Fudan University · Dana-Farber Cancer Institute · Pfizer
+93 more · H. Lee Moffitt Cancer Center and Research Institute · Hoffmann-La Roche · M.D. Anderson Cancer Center · MedSIR · UNICANCER · Yale University · Arcus Biosciences, Inc. · British Columbia Cancer Agency · GBG Forschungs GmbH · Guangzhou Medical University · IRCCS San Raffaele · Liaoning Cancer Hospital & Institute · Massachusetts General Hospital · Memorial Sloan Kettering Cancer Center · SWOG Cancer Research Network · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · The University of Texas Health Science Center at San Antonio · Tianjin Medical University Cancer Institute and Hospital · University of Kansas Medical Center · West German Study Group · Adrienne G. Waks · Alliance Foundation Trials, LLC. · Ana C Garrido-Castro, MD · Apices Soluciones S.L. · Array BioPharma · Asia-Pacific Gynecologic Oncology Trials Group · Austrian Breast & Colorectal Cancer Study Group · Avenzo Therapeutics, Inc. · Bindu R Potugari · Breast Cancer Research Foundation · Bristol-Myers Squibb · British Columbia Cancer Agency · Canadian Cancer Trials Group · Cancer Trials Ireland · Chinese University of Hong Kong · Claudia Guerrieri · Dragonfly Therapeutics · EMD Serono Research & Development Institute, Inc. · ETOP IBCSG Partners Foundation · European Network of Gynaecological Oncological Trial Groups (ENGOT) · First Hospital of China Medical University · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Fundación GECP · Fundación para el Progreso de la Oncología en Cantabria · GOG Foundation · Genentech, Inc. · Georgetown University · German Cancer Research Center · Gilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and Astellas · Henry Ford Health System · High Research · Hoosier Cancer Research Network · Hunan Cancer Hospital · IDEAYA Biosciences · ImmunityBio, Inc. · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Johns Hopkins University · Laura Huppert, MD, BA · MFAR · Maastricht University Medical Center · Marengo Therapeutics, Inc. · Merck KGaA, Darmstadt, Germany · Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics · NSABP Foundation Inc · National Cancer Center, China · National Taiwan University Hospital · National University Hospital, Singapore · Nir Peled · Novartis Pharmaceuticals · Peking Union Medical College · Peking University Hospital of Stomatology · Reshma L. Mahtani, D.O. · SOLTI Breast Cancer Research Group · Second Affiliated Hospital, School of Medicine, Zhejiang University · all 99 on the full record

Regulatory milestones approvals, filings & regulatory actions · 14 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Filed Her2-receptor negative breast cancer 1 milestone
Filed China (NMPA) Trodelvy Her2-receptor negative breast cancer —

“Regulatory review is also underway in Singapore and China with applications submitted by Everest Medicines.” gilead.com ↗
Filed progesterone-receptor positive breast cancer 2 milestones
Filed EU (EMA) Trodelvy progesterone-receptor positive breast cancer 2023-01-03

“The European Medicines Agency has also validated a Type II Variation Marketing Authorization Application for Trodelvy in HR+/HER2- metastatic breast cancer.” gilead.com ↗

“Announced that the European Medicines Agency has validated a Type II variation of the Marketing Authorization Application for Trodelvy” gilead.com ↗

“the European Medicines Agency (EMA) has validated a Type II variation Marketing Authorization Application (MAA) for Trodelvy” gilead.com ↗
Filed US (FDA) Trodelvy progesterone-receptor positive breast cancer 2022-10-11

“the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for Trodelvy” gilead.com ↗
Filed triple-negative breast carcinoma 5 milestones
Filed EU (EMA) Trodelvy triple-negative breast carcinoma 2026-05-22

“Gilead has submitted a supplemental filing to the European Medicines Agency for Trodelvy in combination with Keytruda ® (pembrolizumab) for patients with PD-L1 positive...” gilead.com ↗

“Gilead has submitted a supplemental filing to the European Medicines Agency for Trodelvy in combination with Keytruda ® (pembrolizumab)” gilead.com ↗
Filed US (FDA) Trodelvy triple-negative breast carcinoma 2026-05-21

“Gilead has also submitted supplemental filings to the European Medicines Agency and the U.S. Food and Drug Administration for Trodelvy in combination with Keytruda” gilead.com ↗

“Gilead has also submitted an application to the U.S. Food and Drug Administration for approval of Trodelvy in this indication based on the ASCENT-03 study.” gilead.com ↗

“In the U.S., Gilead has also submitted supplemental filings to the Food and Drug Administration (FDA) for Trodelvy for the first-line treatment” gilead.com ↗

“Outside of Europe, Gilead has submitted supplemental applications to the U.S. Food and Drug Administration (FDA) for approval of Trodelvy” gilead.com ↗

“In the U.S., Gilead has also submitted supplemental filings to the Food and Drug Administration (FDA) for Trodelvy” gilead.com ↗
Filed Other Trodelvy triple-negative breast carcinoma 2021-04-07

“Regulatory submissions for Trodelvy in metastatic TNBC have been filed in the United Kingdom, Canada, Switzerland and Australia” gilead.com ↗

“Regulatory review is also underway in Singapore and China with applications submitted by Everest Medicines.” gilead.com ↗
Filed EU (EMA) Trodelvy triple-negative breast carcinoma 2021-04-07

“European Medicines Agency (“EMA”) validated the Marketing Authorization Application and granted accelerated review for Trodelvy for the treatment of mTNBC.” gilead.com ↗

“The European Medicines Agency has also validated a Marketing Authorization Application for Trodelvy in the European Union.” gilead.com ↗

“the European Medicines Agency validated a Marketing Authorization Application for Trodelvy in March” gilead.com ↗
Filed UK (MHRA) Trodelvy triple-negative breast carcinoma 2021-04-07

“Regulatory submissions for Trodelvy in metastatic TNBC have been filed in the United Kingdom, Canada, Switzerland and Australia” gilead.com ↗
Approved Indication not stated 3 milestones
Label expansions (4) US (FDA) TRODELVY — 2021-04-07 – 2026-06-24 fda.gov ↗
Approved EU (EMA) Trodelvy — 2021-11-22 europa.eu ↗
Approved US (FDA) TRODELVY — 2020-04-22 fda.gov ↗

Trials 128 · started per year

today
US approved 2020
EU approved 2021
1
1
2
3
8
10
12
9
17
29
20
16
2013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial · 1 met primary
Phase 0 NCT03995706 Jul 2019 → Jun 2022 glioblastoma The University of Texas Health Science Center at San Antonio Completed Met primary
Phase 19 trials
Phase 1 NCT07674615 Jul 2026 → Jun 2027 expected fallopian tube carcinoma, malignant epithelial tumor of ovary, primary peritoneal carcinoma Shanghai Gynecologic Oncology Group Not yet recruiting No outcome recorded
Phase 1 NCT07163481 Oct 2025 → Dec 2026 expected female breast carcinoma Hunan Cancer Hospital Not yet recruiting No outcome recorded
Phase 1 NCT06065371 Nov 2024 → Dec 2026 expected digestive system cancer Henry Ford Health System Recruiting No outcome recorded
Phase 1 NCT05833867 Apr 2024 → Dec 2026 expected infiltrating bladder urothelial carcinoma Shilpa Gupta, MD Recruiting No outcome recorded
Phase 1 NCT06167317 Jan 2024 → Sep 2028 expected cancer Gilead Sciences Recruiting No outcome recorded
Phase 1 NCT05774886 May → Sep 2023 female breast carcinoma, triple-negative breast carcinoma Dana-Farber Cancer Institute Withdrawn No outcome recorded
Phase 1 NCT05143229 Mar 2022 → Jan 2025 overdue breast cancer University of Kansas Medical Center Active not recruiting No outcome recorded
Phase 1 NCT04794699 Apr 2021 → Jan 2027 expected cancer IDEAYA Biosciences Active not recruiting No outcome recorded
Phase 1 NCT04617522 Apr 2021 → Dec 2026 expected liver failure Gilead Sciences Recruiting No outcome recorded
Phase 1/222 trials · 1 missed
Phase 1/2 NCT07328490 Apr 2026 small cell lung carcinoma National Cancer Institute (NCI) Withdrawn No outcome recorded Stop: Enrollment
Phase 1/2 NCT06462092 Jan 2026 → Jan 2027 expected malignant leptomeningeal tumor Guangzhou Medical University Recruiting No outcome recorded
Phase 1/2 NCT07011654 Sep 2025 → Jul 2028 expected triple-negative breast carcinoma M.D. Anderson Cancer Center Recruiting No outcome recorded
Phase 1/2 NCT06926920 Apr 2025 → Jun 2028 expected triple-negative breast carcinoma Gilead Sciences Recruiting No outcome recorded
Phase 1/2 NCT06827613 Mar 2025 → Jan 2027 expected hormone receptor-positive breast cancer, triple-negative breast carcinoma Marengo Therapeutics, Inc. Recruiting No outcome recorded
Phase 1/2 NCT06238921 Dec 2024 → Feb 2027 expected triple-negative breast carcinoma H. Lee Moffitt Cancer Center and Research Institute Recruiting No outcome recorded
Phase 1/2 NCT06123468 Apr 2024 → Jan 2026 gastroesophageal adenocarcinoma Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Completed No outcome recorded
Phase 1/2 NCT06328387 Jan 2024 → Feb 2026 breast cancer Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Unknown No outcome recorded
Phase 1/2 NCT05867251 Aug 2023 → Jan 2028 expected endometrial cancer, fallopian tube cancer, hormone receptor-positive breast cancer, malignant epithelial tumor of ovary +2 Avenzo Therapeutics, Inc. Recruiting No outcome recorded
Phase 1/2 NCT05101096 Oct 2021 → May 2027 expected hormone receptor-positive breast cancer, triple-negative breast carcinoma, urothelial carcinoma Gilead Sciences Active not recruiting No outcome recorded
Phase 274 trials · 1 missed
Phase 2 NCT07504588 Sep 2026 → Apr 2029 expected fallopian tube endometrioid adenocarcinoma, fallopian tube serous adenocarcinoma, ovarian endometrioid adenocarcinoma, primary peritoneal serous/papillary carcinoma National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 2 NCT07825753 Sep 2026 → Sep 2027 expected breast cancer, pancreatic adenocarcinoma Fudan University Not yet recruiting No outcome recorded
Phase 2 NCT07393555 Aug 2026 → Nov 2028 expected non-small cell lung carcinoma SWOG Cancer Research Network Not yet recruiting No outcome recorded
Phase 2 NCT07367178 Jul 2026 → Jun 2027 expected hormone receptor-positive breast cancer, triple-negative breast carcinoma MedSIR Not yet recruiting No outcome recorded
Phase 2 NCT07339059 Jun 2026 → Feb 2029 expected small cell lung carcinoma Bindu R Potugari Recruiting No outcome recorded
Phase 2 NCT07492914 May → Dec 2026 expected head and neck squamous cell carcinoma West China Hospital Recruiting No outcome recorded
Phase 2 NCT07134556 Apr 2026 → May 2028 triple-negative breast carcinoma MedSIR Withdrawn No outcome recorded
Phase 2 NCT06889610 Mar 2026 → Dec 2027 expected colorectal cancer, melanoma, triple-negative breast carcinoma Fudan University Recruiting No outcome recorded
Phase 2 NCT07471776 Mar 2026 → Mar 2028 expected Her2-receptor negative breast cancer Fudan University Recruiting No outcome recorded
Phase 2 NCT07438600 Feb 2026 → Feb 2027 expected non-small cell lung carcinoma Tianjin Medical University Cancer Institute and Hospital Not yet recruiting No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT06243393 Apr 2024 → Aug 2028 expected colorectal cancer University Hospital Heidelberg Recruiting No outcome recorded
Phase 318 trials · 5 met primary · 3 missed
Phase 3 NCT07178730 Jun 2026 → Mar 2033 expected triple-negative breast carcinoma West German Study Group Not yet recruiting No outcome recorded
Phase 3 NCT06524544 Dec 2025 → Dec 2030 expected urothelial carcinoma National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 3 NCT06801834 Apr 2025 → Oct 2029 expected small cell lung carcinoma Gilead Sciences Recruiting No outcome recorded
Phase 3 NCT06431633 Feb 2025 → Nov 2031 expected non-small cell lung carcinoma Fundación GECP Recruiting No outcome recorded
Phase 3 NCT06081244 Oct 2024 → Sep 2029 expected triple-negative breast carcinoma West German Study Group Recruiting No outcome recorded
Phase 3 NCT06486441 Aug 2024 → Jun 2029 expected endometrial cancer Gilead Sciences Active not recruiting No outcome recorded
Phase 3 NCT05552001 Oct 2023 → May 2026 overdue triple-negative breast carcinoma UNICANCER Recruiting No outcome recorded
Phase 3 NCT05840211 May 2023 → Apr 2028 expected breast cancer Gilead Sciences Active not recruiting Missed primary
Phase 3 NCT05609968 Feb 2023 → Jan 2027 expected non-small cell lung carcinoma Merck Sharp & Dohme LLC Active not recruiting No outcome recorded
Phase 3 NCT05633654 Dec 2022 → Jun 2027 expected triple-negative breast carcinoma Gilead Sciences Recruiting No outcome recorded
Phase 42 trials
Phase 4 NCT07162259 Oct 2025 → Dec 2027 expected breast cancer Yan Xue Not yet recruiting No outcome recorded
Phase 4 NCT04319198 Aug 2020 → Oct 2024 metastatic neoplasm Gilead Sciences Completed No outcome recorded
Phase not applicable1 trial
— NCT06341478 Mar 2024 → Mar 2026 overdue urinary bladder cancer IRCCS San Raffaele Recruiting No outcome recorded
Comparator or background therapy18 trials
Phase 1 NCT05006794 Background Sep 2021 → Jun 2025 cancer Gilead Sciences Terminated No outcome recorded Stop: Business
Phase 1/2 NCT06963905 Comparator Dec 2025 → Dec 2030 expected triple-negative breast carcinoma Yale University Recruiting No outcome recorded
Phase 1/2 NCT06612203 Background Jan 2025 → Feb 2027 expected breast cancer MedSIR Active not recruiting No outcome recorded
Phase 2 NCT07474558 Background Sep 2026 → Jan 2030 expected alopecia, metastatic neoplasm Jules Bordet Institute Not yet recruiting No outcome recorded
Phase 2 NCT07394218 Background Dec 2025 → Mar 2028 expected Her2-receptor negative breast cancer Fudan University Recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 54

DateIssuerRelease
2026-08-24 Gilead Sciences Regulatory European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status gilead.com ↗
Trodelvy plus Keytruda is the first and only antibody-drug conjugate (ADC) plus immunotherapy combination to be approved in first-line metastatic TNBC in the European Union’s 27 member states, as well as Norway, Iceland and Liechtenstein.
2026-07-24 Gilead Sciences Regulatory CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer gilead.com ↗
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorization of Trodelvy ® (sacituzumab govitecan-hziy) in combination with Keytruda ® (pembrolizumab), for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and whose tumors express PD-L1 with a combined positive score (CPS ≥10).
2026-06-25 Merck Sharp & Dohme LLC Regulatory FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC) merck.com ↗
2026-06-24 Gilead Sciences Regulatory U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer gilead.com ↗
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy ® (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed antibody-drug conjugate (ADC), for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC).
2026-06-23 Gilead Sciences Regulatory European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors gilead.com ↗
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy ® (sacituzumab govitecan-hziy) as monotherapy for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and are not candidates for PD-1 or PD-L1 inhibitor therapy.
2026-06-08 Merck Sharp & Dohme LLC Results Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study merck.com ↗
A numerical improvement in PFS was observed, but did not reach statistical significance.
2026-06-08 Gilead Sciences Results Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study gilead.com ↗
A numerical improvement in PFS was observed, but did not reach statistical significance.
2026-05-22 Gilead Sciences Regulatory Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors gilead.com ↗
2026-01-21 Gilead Sciences Results New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer gilead.com ↗
ASCENT-04 successfully met its primary endpoint of progression-free survival (PFS) with a 35% (HR: 0.65; p<0.001) reduced risk of disease progression or death for Trodelvy plus Keytruda (n=221) versus standard of care Keytruda plus chemotherapy (n=222).
2025-11-07 Gilead Sciences Results Gilead Provides Update on Phase 3 ASCENT-07 Study gilead.com ↗
Overall survival is a key secondary endpoint and was not mature at the time of the primary analysis; however, an early trend was observed favoring patients treated with Trodelvy compared to chemotherapy.
2025-10-19 Gilead Sciences Results Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study gilead.com ↗
ASCENT-03 successfully met its primary endpoint of PFS with a 38% reduced risk of disease progression or death for Trodelvy versus chemotherapy (HR: 0.62; p<0.0001).
2025-09-08 IDEAYA Biosciences Results IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer ideayabio.com ↗
Overall response rate ( ORR ) of 57% (4/7; 3cPR+1uPR) in patients treated with a combination of 30 mg IDE397 plus 7.5mg/kg Trodelvy ® (Dose level 2);

All press releases naming this drug 69 releases

DateIssuerRelease

Evidence & citations 13 cited values

Every value below carries the sentence it was read from. 154 sources stand behind the page.

FieldValueCited text
Known as sacituzumab govitecan “Participants will receive 6 cycles of a standard intravenous or oral chemotherapy regimen or an Antibody-Drug Conjugate (ADC), selected by the investigator from...” NCT07371910 ↗
120

“Sacituzumab govitecan (SG) significantly improved progression-free survival (PFS) and overall survival (OS) versus chemotherapy in hormone receptor-positive human epidermal...” PMID 39354196 ↗ Oct 2024

“Sacituzumab govitecan (brand name: TRODELVY®) is a cancer treatment, called an antibody-drug conjugate, approved in multiple countries for certain types of breast cancer that...” PMID 41277126 ↗ Nov 2025

“BACKGROUND: Sacituzumab govitecan (SG) is a Trop-2-directed antibody-drug conjugate approved outside Japan for second-line and later metastatic triple-negative breast cancer...” PMID 39302614 ↗ Sep 2024

“antibody-drug conjugates (ADCs) such as sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) have demonstrated significant activity in HR+/HER2- breast cancer” NCT07162259 ↗

“Sacituzumab govitecan is an antibody-drug conjugate that targets Trop-2-expressing cells and is covalently attached to the topoisomerase I inhibitor SN-38.” NCT06065371 ↗

“TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer” NCT07271992 ↗

“Sacituzumab govitecan is a trophoblast cell-surface antigen 2-directed antibody-drug conjugate approved for certain types of breast cancer.” PMID 41073155 ↗ Sep 2025

“ADC therapy includes sacituzumab govitecan or trastuzumab deruxtecan administered intravenously according to standard dosing schedules.” NCT07394218 ↗

“Sacituzumab govitecan (SG) is a novel antibody-drug conjugate, targeting human trophoblast cell-surface antigen 2 (Trop-2).” PMID 36621000 ↗ Jan 2023

“Multimodal ablation combined with pucotenlimab and TPC or sacituzumab govitecan, eribulin,gemcitabine,UTD1” NCT06889610 ↗

Show 110 more sources
Known as hRS7-SN38 “A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer” NCT01631552 ↗
Known as HRS7-SN38-ANTIBODY-DRUG-CONJUGATE ChEMBL registry synonym — accepted as the source's own label CHEMBL3545262 ↗
Known as IMMU-132 “Sacituzumab govitecan (SG), or IMMU-132 is an investigational new drug that utilizes an antibody-drug conjugate (ADC) to target and kill epithelial bladder cancer cells.” NCT05833867 ↗
5

“A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer” NCT01631552 ↗

“This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132).” NCT05838521 ↗

“* Sacituzumab govitecan (IMMU-132)” NCT04448886 ↗

NCT02161679 ↗

NCT04320693 ↗
Known as Sacituzumab govitecan-hziy “Sacituzumab govitecan-hziy (SG), the anti-Trop-2 antibody-drug conjugate, resulted in a significant survival benefit over chemotherapy in patients with metastatic...” PMID 35728046 ↗ May 2022
30

“Sacituzumab govitecan-hziy is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug called govitecan-hziy.” NCT06524544 ↗

“Sacituzumab govitecan-hziy (SG), the anti-Trop-2 antibody-drug conjugate” PMID 35728046 ↗ May 2022

“Sacituzumab Govitecan-hziy (SG)” NCT05089734 ↗

NCT04143711 ↗

NCT04639986 ↗

NCT04958785 ↗

NCT05840211 ↗

NCT05008510 ↗

NCT06477419 ↗

NCT01631552 ↗

Show 20 more sources
Known as SG ClinicalTrials.gov intervention name — accepted as the source's own label NCT04381832 ↗
Known as Trodelvy “This arm of the Strata PATH trial will assess the clinical benefit of Trodelvy® (sacituzumab govitecan) in patients with advanced solid tumors and are Trop2 Treatment Response...” NCT05097599 ↗
2

“Sacituzumab govitecan is an antibody-drug conjugate, comprising a topoisomerase-I inhibiting camptothecin, SN-38, linked to a humanized antibody targeting trophoblastic...” NCT04826341 ↗

“Sacituzumab govitecan (SG; Trodelvy®) is a trophoblast cell-surface antigen 2 (Trop-2)- directed antibody-drug conjugate” NCT07063212 ↗
Action Deplete “delivers SN-38 to kill them” NCT03971409 ↗
Action Inhibit “DNA topoisomerase I inhibitor” CHEMBL3545262 ↗
Modality Other / unclassified “antibody-drug conjugate sacituzumab govitecan” PMID 33093337 ↗ Feb 2021
Route Intravenous “Administered via intravenous (IV) infusion” NCT01631552 ↗
Target TACSTD2 “delivering targeted cytotoxic effects to TROP2-overexpressing tumor cells” NCT07492914 ↗
Target TOP1 “DNA topoisomerase I inhibitor” CHEMBL3545262 ↗